Latest News for: hcw

Edit

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules (Form 8-K) (HCW Biologics Inc)

Public Technologies 19 Feb 2026
). HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules. MIRAMAR, Fla., February 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company"), (NASDAQ ... Disclaimer. HCW Biologics Inc.
Edit

Supplemental Prospectus (Form 424B4) (HCW Biologics Inc)

Public Technologies 19 Feb 2026
Unless the context otherwise requires, the terms "we," "us," "our," the "Company," "HCW Biologics," "HCWB," and "our business" refer to HCW Biologics Inc ... HCW Biologics Inc.
Edit

Notice of Effectiveness (Form EFFECT) (HCW Biologics Inc)

Public Technologies 18 Feb 2026
) UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 ... HCW Biologics Inc ... HCW Biologics Inc.
Edit

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Nasdaq Globe Newswire 18 Feb 2026
MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ ... The closing of the offering is expected to occur on or about February 19, 2026, subject to the satisfaction of customary closing conditions. .
Edit

Amendment to Initial Registration Statement (Form S-1/A) (HCW Biologics Inc)

Public Technologies 17 Feb 2026
HCW BIOLOGICS INC ... HCW Biologics Inc ... HCW Biologics is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases.
Edit

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed ...

Nasdaq Globe Newswire 13 Feb 2026
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune ... .
Edit

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune (Form 8-K) (HCW Biologics Inc)

Public Technologies 13 Feb 2026
HCW Biologics and WY Biotech ... HCW Biologics receiving cash fee and co-founder shares in Trimmune valued at $7.0 million ... HCW Biologics retains royalty-free option to reclaim the rights to the Americas territory ... ("HCW Biologics") (NASDAQ.
Edit

Initial Registration Statement (Form S-1) (HCW Biologics Inc)

Public Technologies 11 Feb 2026
HCW BIOLOGICS INC ... HCW Biologics Inc ... HCW Biologics is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases.
Edit

Material Event (Form 8-K) (HCW Biologics Inc)

Public Technologies 31 Dec 2025
As previously disclosed, on August 19, 2025, HCW Biologics Inc. (the "Company" or "HCW Biologics") was notified by the Listing Qualifications Staff (the ... HCW Biologics Inc.
Edit

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules (Form 8-K) (HCW Biologics Inc)

Public Technologies 20 Nov 2025
). HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules. MIRAMAR, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ ... Disclaimer. HCW Biologics Inc.
Edit

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

Nasdaq Globe Newswire 19 Nov 2025
MIRAMAR, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ ... .
Edit

Material Agreement (Form 8-K) (HCW Biologics Inc)

Public Technologies 19 Nov 2025
) Item 1.01 Entry into a Material Definitive Agreement. On November 17, 2025, HCW Biologics Inc. (the "Company") and Beijing Trimmune Biotech Co., Ltd ... to Trimmune ... Attachments Original document Permalink. Disclaimer. HCW Biologics Inc ... (noodl.
Edit

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

Nasdaq Globe Newswire 18 Nov 2025
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial ... .
Edit

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease (Form 8-K) (HCW Biologics Inc)

Public Technologies 18 Nov 2025
). HCW Biologics Announces. Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease ... MIRAMAR, Fla., November 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc ... Mary E ... About HCW Biologics.. HCW Biologics Inc ... HCW Biologics Inc.

Article Search

tools
×
×
×
×